Search clinical trials for: Tiotropium

Total 426 results

Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Novartis Pharmaceuticals

Withdrawn

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control (INITIATE)

Chronic Obstructive Pulmonary Disease (COPD)
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
University of Crete

Completed

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Merck Sharp & Dohme LLC
Novartis; Integrated Therapeutics Group

Completed

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

Pulmonary Disease, Chronic Obstructive
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Poland, Czech Republic
GlaxoSmithKline

Completed

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects (SCO116572)

Pulmonary Disease, Chronic Obstructive

Japan
National Cancer Institute (NCI)

Completed

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Rectal Cancer | Colon Cancer | Precancerous Condition

United States
Novo Nordisk A/S

Completed

Observational Study on Safety of Self-titration of Once Daily Levemir® (SOLVE™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novartis Pharmaceuticals

Completed

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (INHALATOR)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
Seoul National University Hospital

Completed

Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
Boehringer Ingelheim

Completed

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Pulmonary Disease, Chronic Obstructive

Austria, Germany, Canada, United States, Poland, Belgium, Portugal, United Kingdom, Australia, Denmark, New Zealand
AstraZeneca

Completed

Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Czech Republic, Germany, Hungary, Poland
AstraZeneca

Completed

Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) (HELIOS)

Chronic Obstructive Pulmonary Disease

France, Germany, Italy, Spain, United Kingdom, Austria, Hungary
Novo Nordisk A/S

Completed

Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovenia
GlaxoSmithKline

Completed

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (ADC111114)

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
GlaxoSmithKline

Completed

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Pulmonary Disease, Chronic Obstructive

Japan
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Indonesia
GlaxoSmithKline

Completed

Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Finland, Russian Federation, United Kingdom
GlaxoSmithKline

Completed

SERETIDE Plus Tiotropium Versus Individual Components

Pulmonary Disease, Chronic Obstructive

Belgium, United Kingdom
Boehringer Ingelheim

Completed

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Canada, Finland, France, Germany, Hungary, Italy, Spain, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Pulmonary Disease, Chronic Obstructive
The First Affiliated Hospital of Guangzhou Medical...
Boehringer Ingelheim; Rundo International Pharmaceutical Research & Development...

Completed

Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China (Tie-COPD)

Chronic Obstructive Pulmonary Disease

China
Mel Shiuann-Sheng Lee
Novartis

Completed

Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

Functional Outcomes | Prevention of BMD Loss After THR | Serum Markers of Bone Turnover

Taiwan
3M
Quotient Clinical

Completed

Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products

Healthy

United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Asthma

United States, Bulgaria, Canada, Germany, Guatemala, Hungary, Korea, Republic of, Latvia, Lithuania, Norway, Portugal, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
University of Alberta

Withdrawn

Tiotropium for Smoking Asthmatics Study

Asthma

Canada
University of Saskatchewan

Completed

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

Asthma

Canada
Novartis Pharmaceuticals

Completed

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

COPD

Germany, Spain, United Kingdom, Italy
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

Chronic Obstructive Pulmonary Disease

Italy
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden
Boehringer Ingelheim

Completed

Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines

Pulmonary Disease, Chronic Obstructive

Austria
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

Asthma

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Germany, Guatemala, Hungary, Latvia, Lithuania, Poland, Romania, Russian Federation, Slovakia, Ukraine
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Austria, Canada, Germany, Greece, New Zealand, Norway, Slovakia, South Africa, Sweden
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, South Africa, Spain, United Kingdom
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Unknown

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

Spinal Cord Injury

United States
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD) (EMERAL)

COPD

Mexico

3

Subscribe